Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015
Abstract Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landma...
Gespeichert in:
| Veröffentlicht in: | Mayo Clinic proceedings 2015-10, Vol.90 (10), p.1440-1454 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1454 |
|---|---|
| container_issue | 10 |
| container_start_page | 1440 |
| container_title | Mayo Clinic proceedings |
| container_volume | 90 |
| creator | Thompson, Philip A., MBBS Kantarjian, Hagop M., MD Cortes, Jorge E., MD |
| description | Abstract Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future. |
| doi_str_mv | 10.1016/j.mayocp.2015.08.010 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5656269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A433121049</galeid><els_id>S0025619615006710</els_id><sourcerecordid>A433121049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c643t-9fc9dd53972aa5f8edbbdfe52b27c0a5df2e85decdaad99d300508a2a83b68c3</originalsourceid><addsrcrecordid>eNqFUl2L1DAULaK44-o_ECkI4kvHm7RJGwRhGT9hxAfnPaTJ7Uxm02ZM2oX596Z03dV98SkPOfece865WfaSwJoA4e-O616dvT6tKRC2hmYNBB5lKyIqWjBW8cfZCoCyghPBL7JnMR4BoBaieppdUF6VleBilb3_aNV-8NHGXA0m3wVUY4_DmPsu3xyCH6zOv5_ReWvyLU7X2FuV2yGfRZ9nTzrlIr64fS-z3edPu83XYvvjy7fN1bbQSWYsRKeFMawUNVWKdQ2atjUdMtrSWoNipqPYMIPaKGWEMCUAg0ZR1ZQtb3R5mX1YaE9T26PRabugnDwF26twll5Z-e_PYA9y728k44xTLhLB21uC4H9NGEfZ26jROTWgn6Ik9RxaQvIEff0AevRTGJK7BcVKWpcJ9WZB7ZVDeUDlxkP0bhqtH6K8qsqSUALVrFwtQB18jAG7u60JyLlFeZRLi3IOVEIjU4tp7NXfju-G_tR2Hwmm2G8sBhm1xUGjsQH1KI23_1N4SKCdTV0rd41njPemZaQS5M_5kuZDIgyA14ngN-V-w-E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1719453273</pqid></control><display><type>article</type><title>Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Thompson, Philip A., MBBS ; Kantarjian, Hagop M., MD ; Cortes, Jorge E., MD</creator><creatorcontrib>Thompson, Philip A., MBBS ; Kantarjian, Hagop M., MD ; Cortes, Jorge E., MD</creatorcontrib><description>Abstract Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2015.08.010</identifier><identifier>PMID: 26434969</identifier><identifier>CODEN: MACPAJ</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Care and treatment ; Chronic myeloid leukemia ; Clinical Protocols ; Diagnosis ; Diagnosis, Differential ; Disease Progression ; Humans ; Internal Medicine ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology ; Patient Outcome Assessment ; Philadelphia Chromosome ; Prognosis ; Protein Kinase Inhibitors - classification ; Protein Kinase Inhibitors - pharmacology</subject><ispartof>Mayo Clinic proceedings, 2015-10, Vol.90 (10), p.1440-1454</ispartof><rights>Mayo Foundation for Medical Education and Research</rights><rights>2015 Mayo Foundation for Medical Education and Research</rights><rights>Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</rights><rights>COPYRIGHT 2015 Frontline Medical Communications Inc.</rights><rights>Copyright Mayo Foundation for Medical Education and Research Oct 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c643t-9fc9dd53972aa5f8edbbdfe52b27c0a5df2e85decdaad99d300508a2a83b68c3</citedby><cites>FETCH-LOGICAL-c643t-9fc9dd53972aa5f8edbbdfe52b27c0a5df2e85decdaad99d300508a2a83b68c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1719453273?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26434969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Philip A., MBBS</creatorcontrib><creatorcontrib>Kantarjian, Hagop M., MD</creatorcontrib><creatorcontrib>Cortes, Jorge E., MD</creatorcontrib><title>Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>Abstract Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.</description><subject>Care and treatment</subject><subject>Chronic myeloid leukemia</subject><subject>Clinical Protocols</subject><subject>Diagnosis</subject><subject>Diagnosis, Differential</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology</subject><subject>Patient Outcome Assessment</subject><subject>Philadelphia Chromosome</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - classification</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFUl2L1DAULaK44-o_ECkI4kvHm7RJGwRhGT9hxAfnPaTJ7Uxm02ZM2oX596Z03dV98SkPOfece865WfaSwJoA4e-O616dvT6tKRC2hmYNBB5lKyIqWjBW8cfZCoCyghPBL7JnMR4BoBaieppdUF6VleBilb3_aNV-8NHGXA0m3wVUY4_DmPsu3xyCH6zOv5_ReWvyLU7X2FuV2yGfRZ9nTzrlIr64fS-z3edPu83XYvvjy7fN1bbQSWYsRKeFMawUNVWKdQ2atjUdMtrSWoNipqPYMIPaKGWEMCUAg0ZR1ZQtb3R5mX1YaE9T26PRabugnDwF26twll5Z-e_PYA9y728k44xTLhLB21uC4H9NGEfZ26jROTWgn6Ik9RxaQvIEff0AevRTGJK7BcVKWpcJ9WZB7ZVDeUDlxkP0bhqtH6K8qsqSUALVrFwtQB18jAG7u60JyLlFeZRLi3IOVEIjU4tp7NXfju-G_tR2Hwmm2G8sBhm1xUGjsQH1KI23_1N4SKCdTV0rd41njPemZaQS5M_5kuZDIgyA14ngN-V-w-E</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Thompson, Philip A., MBBS</creator><creator>Kantarjian, Hagop M., MD</creator><creator>Cortes, Jorge E., MD</creator><general>Elsevier Inc</general><general>Frontline Medical Communications Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4U-</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151001</creationdate><title>Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015</title><author>Thompson, Philip A., MBBS ; Kantarjian, Hagop M., MD ; Cortes, Jorge E., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c643t-9fc9dd53972aa5f8edbbdfe52b27c0a5df2e85decdaad99d300508a2a83b68c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Care and treatment</topic><topic>Chronic myeloid leukemia</topic><topic>Clinical Protocols</topic><topic>Diagnosis</topic><topic>Diagnosis, Differential</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology</topic><topic>Patient Outcome Assessment</topic><topic>Philadelphia Chromosome</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - classification</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Philip A., MBBS</creatorcontrib><creatorcontrib>Kantarjian, Hagop M., MD</creatorcontrib><creatorcontrib>Cortes, Jorge E., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Philip A., MBBS</au><au>Kantarjian, Hagop M., MD</au><au>Cortes, Jorge E., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>90</volume><issue>10</issue><spage>1440</spage><epage>1454</epage><pages>1440-1454</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><coden>MACPAJ</coden><abstract>Abstract Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>26434969</pmid><doi>10.1016/j.mayocp.2015.08.010</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-6196 |
| ispartof | Mayo Clinic proceedings, 2015-10, Vol.90 (10), p.1440-1454 |
| issn | 0025-6196 1942-5546 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5656269 |
| source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Care and treatment Chronic myeloid leukemia Clinical Protocols Diagnosis Diagnosis, Differential Disease Progression Humans Internal Medicine Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology Patient Outcome Assessment Philadelphia Chromosome Prognosis Protein Kinase Inhibitors - classification Protein Kinase Inhibitors - pharmacology |
| title | Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A21%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20and%20Treatment%20of%20Chronic%20Myeloid%20Leukemia%20in%202015&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Thompson,%20Philip%20A.,%20MBBS&rft.date=2015-10-01&rft.volume=90&rft.issue=10&rft.spage=1440&rft.epage=1454&rft.pages=1440-1454&rft.issn=0025-6196&rft.eissn=1942-5546&rft.coden=MACPAJ&rft_id=info:doi/10.1016/j.mayocp.2015.08.010&rft_dat=%3Cgale_pubme%3EA433121049%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1719453273&rft_id=info:pmid/26434969&rft_galeid=A433121049&rft_els_id=S0025619615006710&rfr_iscdi=true |